Loading…

Solubility enhancement of celecoxib using solidified Tween 80 for the formulation of tablet dosage forms

Celecoxib is a non-steroidal, anti-inflammatory drug used in the treatment of pain and inflammation associated with rheumatoid arthritis, and several other inflammatory disorders. It is a class II compound according to the Biopharmaceutics Classification System owing to its low water solubility and...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pharmaceutical investigation 2015, 45(5), , pp.449-460
Main Authors: Chakma, Suharto, Khadka, Prakash, Jo, Kanghee, Kim, Hyeongmin, Ro, Jieun, Park, Kyunghee, Karki, Sandeep, Barua, Sonia, Lee, Jaehwi
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c2361-df22711ca963e25256542d03dfa26b990d948edfe8625e7e9f919f733ae2ff7d3
cites cdi_FETCH-LOGICAL-c2361-df22711ca963e25256542d03dfa26b990d948edfe8625e7e9f919f733ae2ff7d3
container_end_page 460
container_issue 5
container_start_page 449
container_title Journal of pharmaceutical investigation
container_volume 45
creator Chakma, Suharto
Khadka, Prakash
Jo, Kanghee
Kim, Hyeongmin
Ro, Jieun
Park, Kyunghee
Karki, Sandeep
Barua, Sonia
Lee, Jaehwi
description Celecoxib is a non-steroidal, anti-inflammatory drug used in the treatment of pain and inflammation associated with rheumatoid arthritis, and several other inflammatory disorders. It is a class II compound according to the Biopharmaceutics Classification System owing to its low water solubility and high membrane permeability. The objective of this study was to improve the solubility and dissolution rate of celecoxib using solid surfactant technology that might be useful in developing solid dosage forms. Solid surfactant was developed by mixing and grinding together a liquid surfactant (Tween 80) with various inorganic carriers like Fujicalin ® (Dibasic Calcium Phosphate Anhydrous), Pineflow ® (Porous-structured Maltodextrin), Neusilin ® (Magnesium Alumino metasilicate) and Aerosil ® (Colloidal Silicon dioxide) in a mortar and pestle in different ratios of liquid surfactant and the carrier to obtain solid surfactants. The celecoxib tablets prepared with solid surfactants were then evaluated for their solubility and dissolution properties. Among the fillers used, Fujicalin showed the highest solubilization capacity for celecoxib. The dissolution behaviors of various tablets prepared with solidified surfactants were compared to those of conventional celecoxib tablets in a simulated gastric fluid. Celecoxib tablets prepared using solidified surfactants showed improved dissolution behaviors when compared to the conventional counterparts. Fujicalin solidified Tween 80 was further analyzed by powder X-ray diffraction analysis, differential scanning calorimetry thermographs and reverse phase high performance liquid chromatography.
doi_str_mv 10.1007/s40005-015-0192-1
format article
fullrecord <record><control><sourceid>nrf_cross</sourceid><recordid>TN_cdi_nrf_kci_oai_kci_go_kr_ARTI_960778</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>oai_kci_go_kr_ARTI_960778</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2361-df22711ca963e25256542d03dfa26b990d948edfe8625e7e9f919f733ae2ff7d3</originalsourceid><addsrcrecordid>eNp9kF1LwzAUhoMoOHQ_wLtcelNN0iZtLsfwYzAQdF6HtDnZsnWJJC26f29rd-1FeAPneQ6cF6E7Sh4oIeVjKgghPCN0fJJl9ALNGJF5JhgtLs9_zjm7RvOU9mSkBa0qOUO7j9D2tWtdd8Lgd9o3cATf4WBxAy004cfVuE_Ob3EKrTPOOjB48w3gcUWwDRF3Oxjz2Le6c8GPaqfrFjpsQtLbaZhu0ZXVbYL5OW_Q5_PTZvmard9eVsvFOmtYLmhmLGMlpY2WIgfGGRe8YIbkxmomaimJkUUFxkIlGIcSpJVU2jLPNTBrS5PfoPtpr49WHRqngnZ_uQ3qENXifbNSUpCyrAaUTmgTQ0oRrPqK7qjjSVGixmLVVKwailVjsYoODpucNLB-C1HtQx_9cNE_0i893HuA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Solubility enhancement of celecoxib using solidified Tween 80 for the formulation of tablet dosage forms</title><source>Springer Link</source><creator>Chakma, Suharto ; Khadka, Prakash ; Jo, Kanghee ; Kim, Hyeongmin ; Ro, Jieun ; Park, Kyunghee ; Karki, Sandeep ; Barua, Sonia ; Lee, Jaehwi</creator><creatorcontrib>Chakma, Suharto ; Khadka, Prakash ; Jo, Kanghee ; Kim, Hyeongmin ; Ro, Jieun ; Park, Kyunghee ; Karki, Sandeep ; Barua, Sonia ; Lee, Jaehwi</creatorcontrib><description>Celecoxib is a non-steroidal, anti-inflammatory drug used in the treatment of pain and inflammation associated with rheumatoid arthritis, and several other inflammatory disorders. It is a class II compound according to the Biopharmaceutics Classification System owing to its low water solubility and high membrane permeability. The objective of this study was to improve the solubility and dissolution rate of celecoxib using solid surfactant technology that might be useful in developing solid dosage forms. Solid surfactant was developed by mixing and grinding together a liquid surfactant (Tween 80) with various inorganic carriers like Fujicalin ® (Dibasic Calcium Phosphate Anhydrous), Pineflow ® (Porous-structured Maltodextrin), Neusilin ® (Magnesium Alumino metasilicate) and Aerosil ® (Colloidal Silicon dioxide) in a mortar and pestle in different ratios of liquid surfactant and the carrier to obtain solid surfactants. The celecoxib tablets prepared with solid surfactants were then evaluated for their solubility and dissolution properties. Among the fillers used, Fujicalin showed the highest solubilization capacity for celecoxib. The dissolution behaviors of various tablets prepared with solidified surfactants were compared to those of conventional celecoxib tablets in a simulated gastric fluid. Celecoxib tablets prepared using solidified surfactants showed improved dissolution behaviors when compared to the conventional counterparts. Fujicalin solidified Tween 80 was further analyzed by powder X-ray diffraction analysis, differential scanning calorimetry thermographs and reverse phase high performance liquid chromatography.</description><identifier>ISSN: 2093-5552</identifier><identifier>EISSN: 2093-6214</identifier><identifier>DOI: 10.1007/s40005-015-0192-1</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Biomedical and Life Sciences ; Biomedicine ; Research Article ; 약학</subject><ispartof>Journal of Pharmaceutical Investigation, 2015, 45(5), , pp.449-460</ispartof><rights>The Korean Society of Pharmaceutical Sciences and Technology 2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2361-df22711ca963e25256542d03dfa26b990d948edfe8625e7e9f919f733ae2ff7d3</citedby><cites>FETCH-LOGICAL-c2361-df22711ca963e25256542d03dfa26b990d948edfe8625e7e9f919f733ae2ff7d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002040841$$DAccess content in National Research Foundation of Korea (NRF)$$Hfree_for_read</backlink></links><search><creatorcontrib>Chakma, Suharto</creatorcontrib><creatorcontrib>Khadka, Prakash</creatorcontrib><creatorcontrib>Jo, Kanghee</creatorcontrib><creatorcontrib>Kim, Hyeongmin</creatorcontrib><creatorcontrib>Ro, Jieun</creatorcontrib><creatorcontrib>Park, Kyunghee</creatorcontrib><creatorcontrib>Karki, Sandeep</creatorcontrib><creatorcontrib>Barua, Sonia</creatorcontrib><creatorcontrib>Lee, Jaehwi</creatorcontrib><title>Solubility enhancement of celecoxib using solidified Tween 80 for the formulation of tablet dosage forms</title><title>Journal of pharmaceutical investigation</title><addtitle>Journal of Pharmaceutical Investigation</addtitle><description>Celecoxib is a non-steroidal, anti-inflammatory drug used in the treatment of pain and inflammation associated with rheumatoid arthritis, and several other inflammatory disorders. It is a class II compound according to the Biopharmaceutics Classification System owing to its low water solubility and high membrane permeability. The objective of this study was to improve the solubility and dissolution rate of celecoxib using solid surfactant technology that might be useful in developing solid dosage forms. Solid surfactant was developed by mixing and grinding together a liquid surfactant (Tween 80) with various inorganic carriers like Fujicalin ® (Dibasic Calcium Phosphate Anhydrous), Pineflow ® (Porous-structured Maltodextrin), Neusilin ® (Magnesium Alumino metasilicate) and Aerosil ® (Colloidal Silicon dioxide) in a mortar and pestle in different ratios of liquid surfactant and the carrier to obtain solid surfactants. The celecoxib tablets prepared with solid surfactants were then evaluated for their solubility and dissolution properties. Among the fillers used, Fujicalin showed the highest solubilization capacity for celecoxib. The dissolution behaviors of various tablets prepared with solidified surfactants were compared to those of conventional celecoxib tablets in a simulated gastric fluid. Celecoxib tablets prepared using solidified surfactants showed improved dissolution behaviors when compared to the conventional counterparts. Fujicalin solidified Tween 80 was further analyzed by powder X-ray diffraction analysis, differential scanning calorimetry thermographs and reverse phase high performance liquid chromatography.</description><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Research Article</subject><subject>약학</subject><issn>2093-5552</issn><issn>2093-6214</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNp9kF1LwzAUhoMoOHQ_wLtcelNN0iZtLsfwYzAQdF6HtDnZsnWJJC26f29rd-1FeAPneQ6cF6E7Sh4oIeVjKgghPCN0fJJl9ALNGJF5JhgtLs9_zjm7RvOU9mSkBa0qOUO7j9D2tWtdd8Lgd9o3cATf4WBxAy004cfVuE_Ob3EKrTPOOjB48w3gcUWwDRF3Oxjz2Le6c8GPaqfrFjpsQtLbaZhu0ZXVbYL5OW_Q5_PTZvmard9eVsvFOmtYLmhmLGMlpY2WIgfGGRe8YIbkxmomaimJkUUFxkIlGIcSpJVU2jLPNTBrS5PfoPtpr49WHRqngnZ_uQ3qENXifbNSUpCyrAaUTmgTQ0oRrPqK7qjjSVGixmLVVKwailVjsYoODpucNLB-C1HtQx_9cNE_0i893HuA</recordid><startdate>201510</startdate><enddate>201510</enddate><creator>Chakma, Suharto</creator><creator>Khadka, Prakash</creator><creator>Jo, Kanghee</creator><creator>Kim, Hyeongmin</creator><creator>Ro, Jieun</creator><creator>Park, Kyunghee</creator><creator>Karki, Sandeep</creator><creator>Barua, Sonia</creator><creator>Lee, Jaehwi</creator><general>Springer Netherlands</general><general>한국약제학회</general><scope>AAYXX</scope><scope>CITATION</scope><scope>ACYCR</scope></search><sort><creationdate>201510</creationdate><title>Solubility enhancement of celecoxib using solidified Tween 80 for the formulation of tablet dosage forms</title><author>Chakma, Suharto ; Khadka, Prakash ; Jo, Kanghee ; Kim, Hyeongmin ; Ro, Jieun ; Park, Kyunghee ; Karki, Sandeep ; Barua, Sonia ; Lee, Jaehwi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2361-df22711ca963e25256542d03dfa26b990d948edfe8625e7e9f919f733ae2ff7d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Research Article</topic><topic>약학</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chakma, Suharto</creatorcontrib><creatorcontrib>Khadka, Prakash</creatorcontrib><creatorcontrib>Jo, Kanghee</creatorcontrib><creatorcontrib>Kim, Hyeongmin</creatorcontrib><creatorcontrib>Ro, Jieun</creatorcontrib><creatorcontrib>Park, Kyunghee</creatorcontrib><creatorcontrib>Karki, Sandeep</creatorcontrib><creatorcontrib>Barua, Sonia</creatorcontrib><creatorcontrib>Lee, Jaehwi</creatorcontrib><collection>CrossRef</collection><collection>Korean Citation Index</collection><jtitle>Journal of pharmaceutical investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chakma, Suharto</au><au>Khadka, Prakash</au><au>Jo, Kanghee</au><au>Kim, Hyeongmin</au><au>Ro, Jieun</au><au>Park, Kyunghee</au><au>Karki, Sandeep</au><au>Barua, Sonia</au><au>Lee, Jaehwi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Solubility enhancement of celecoxib using solidified Tween 80 for the formulation of tablet dosage forms</atitle><jtitle>Journal of pharmaceutical investigation</jtitle><stitle>Journal of Pharmaceutical Investigation</stitle><date>2015-10</date><risdate>2015</risdate><volume>45</volume><issue>5</issue><spage>449</spage><epage>460</epage><pages>449-460</pages><issn>2093-5552</issn><eissn>2093-6214</eissn><abstract>Celecoxib is a non-steroidal, anti-inflammatory drug used in the treatment of pain and inflammation associated with rheumatoid arthritis, and several other inflammatory disorders. It is a class II compound according to the Biopharmaceutics Classification System owing to its low water solubility and high membrane permeability. The objective of this study was to improve the solubility and dissolution rate of celecoxib using solid surfactant technology that might be useful in developing solid dosage forms. Solid surfactant was developed by mixing and grinding together a liquid surfactant (Tween 80) with various inorganic carriers like Fujicalin ® (Dibasic Calcium Phosphate Anhydrous), Pineflow ® (Porous-structured Maltodextrin), Neusilin ® (Magnesium Alumino metasilicate) and Aerosil ® (Colloidal Silicon dioxide) in a mortar and pestle in different ratios of liquid surfactant and the carrier to obtain solid surfactants. The celecoxib tablets prepared with solid surfactants were then evaluated for their solubility and dissolution properties. Among the fillers used, Fujicalin showed the highest solubilization capacity for celecoxib. The dissolution behaviors of various tablets prepared with solidified surfactants were compared to those of conventional celecoxib tablets in a simulated gastric fluid. Celecoxib tablets prepared using solidified surfactants showed improved dissolution behaviors when compared to the conventional counterparts. Fujicalin solidified Tween 80 was further analyzed by powder X-ray diffraction analysis, differential scanning calorimetry thermographs and reverse phase high performance liquid chromatography.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><doi>10.1007/s40005-015-0192-1</doi><tpages>12</tpages></addata></record>
fulltext fulltext
identifier ISSN: 2093-5552
ispartof Journal of Pharmaceutical Investigation, 2015, 45(5), , pp.449-460
issn 2093-5552
2093-6214
language eng
recordid cdi_nrf_kci_oai_kci_go_kr_ARTI_960778
source Springer Link
subjects Biomedical and Life Sciences
Biomedicine
Research Article
약학
title Solubility enhancement of celecoxib using solidified Tween 80 for the formulation of tablet dosage forms
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T23%3A40%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-nrf_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Solubility%20enhancement%20of%20celecoxib%20using%20solidified%20Tween%2080%20for%20the%20formulation%20of%20tablet%20dosage%20forms&rft.jtitle=Journal%20of%20pharmaceutical%20investigation&rft.au=Chakma,%20Suharto&rft.date=2015-10&rft.volume=45&rft.issue=5&rft.spage=449&rft.epage=460&rft.pages=449-460&rft.issn=2093-5552&rft.eissn=2093-6214&rft_id=info:doi/10.1007/s40005-015-0192-1&rft_dat=%3Cnrf_cross%3Eoai_kci_go_kr_ARTI_960778%3C/nrf_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2361-df22711ca963e25256542d03dfa26b990d948edfe8625e7e9f919f733ae2ff7d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true